The concomitant usage of ROXICODONE and CYP3A4 inhibitors can improve the plasma concentration of oxycodone, leading to improved or extended opioid consequences. These results could be far more pronounced with concomitant utilization of ROXICODONE and CYP2D6 and CYP3A4 inhibitors, notably when an inhibitor is additional following a secure dose of R